Enter your email address:

Delivered by FeedBurner

Bharat Biotech to start phase III trials for its indigenously developed COVID-19 vaccine

"We are planning to initiate a large phase 3 multicentre study to
evaluate the efficacy and safety of the vaccine," Bharat Biotech said
in a letter to the principal secretaries of these states. The
Hyderabad-based company intends to recruit about 20,000 participants
across India, with about 2,000 people in each state, for the trials.



Post a Comment